Series of Research Papers Take To Task Would-Be Discoverers Of Cytokine Switch Scrutinizing the Knock-out Mice It was the big story out of Amsterdam, summer of 1992. Later that fall at the Vth International Vaccine Cooperative meeting in Chantilly, VA,…
Garbage In, Garbage Out; Could It Be We're Asking Good Questions Of Bad Systems? A Case of Turncoat Tropism -- Or, Living and Dying With "NSI" Why after more than a decade of AIDS research do we still know so…
Another meeting with the (FDA) Commissioner, Rockville, MD, 11 July 1994. Bruce Schackman insisted that we all prepare overheads for our presentations, so we did. We took the train to Washington, D.C., and the Metro to Rockville. There we met…
With Its First Protease Trial Completed, Roche Races to FDA With Lukewarm Results, While Activists Cry 'Foul' "Tarted-Up Anecdotes" Results from ACTG 229, a randomized, 24-week, 302-patient study comparing AZT+ddC+saquinavir (Ro 31-8959, Roche's first protease inhibitor) vs. AZT+saquinavir vs. AZT+ddC,…
Tome of Recommendations Would Abolish ACDDC, Mandate Costing-Out and Establish Advisory Review Group Finding the Political Will ... "The up-coming ACTG re-competition provides an opportunity to re-envision AIDS clinical research for the next 5 years. It looks likely, however, that…
Founded in January 1992, the Treatment Action Group (TAG) is the first and only AIDS organization dedicated solely to advocating for larger and more efficient research efforts, both public and private, towards finding a cure for AIDS. TAG supports the…
Letter sent in response to the press release issued by Sangamo BioSciences on January 9th 2012, the undersigned individuals and organizations are writing to express concern about the status of the SB-728-T development program.
ACTG Investigators Scramble to Convince Industry They Can Produce Searle Study Could Usher in New Era of Efficeincy at ACTG -- or Drive Final Nail in Coffin Like a slap-stick comedy sketch from a kiddy's cartoon escapade, the AIDS Clinical…
ICC's Brainchild Designed to Show Every Drug and Every Combination a Success. Who Could Complain About That? "It's ddC Monotherapy All Over Again" A hastily organized meeting of the newly formed Inter-Company Collaborative (ICC) was convened April 26 at the…
Accelerated Approval Guidelines Expedite Bristol's Launch of New Nucleoside -- In the Absence of Any Proof That It Works Specter of Fast Track Review Haunts Those Who Spawned It "FDA Panel Recommends Drug Despite Incomplete Data." So read the New…